RESUMO
In 1967, Sandy Posey pronounced that sunglasses are essential beachwear ( https://www.youtube.com/watch?v=4HVBEb-GA1Y ). Now, whole-genome sequencing reveals that ultraviolet radiation (UVR) can contribute to melanomas in the iris and conjunctiva, data that provide a molecular explanation for why it is important to protect our eyes from exposure to UVR.
Assuntos
Neoplasias Oculares/prevenção & controle , Melanoma/prevenção & controle , Raios Ultravioleta/efeitos adversos , Neoplasias Oculares/etiologia , Neoplasias Oculares/genética , Dispositivos de Proteção dos Olhos , Redes Reguladoras de Genes/efeitos da radiação , Humanos , Melanoma/etiologia , Melanoma/genética , Sequenciamento Completo do GenomaRESUMO
OBJECTIVES: This collaborative study, based on data collected by the network of Italian Cancer Registries (AIRTUM), describes the burden of rare cancers in Italy. Estimated number of new rare cancer cases yearly diagnosed (incidence), proportion of patients alive after diagnosis (survival), and estimated number of people still alive after a new cancer diagnosis (prevalence) are provided for about 200 different cancer entities. MATERIALS AND METHODS: Data herein presented were provided by AIRTUM population- based cancer registries (CRs), covering nowadays 52% of the Italian population. This monograph uses the AIRTUM database (January 2015), which includes all malignant cancer cases diagnosed between 1976 and 2010. All cases are coded according to the International Classification of Diseases for Oncology (ICD-O-3). Data underwent standard quality checks (described in the AIRTUM data management protocol) and were checked against rare-cancer specific quality indicators proposed and published by RARECARE and HAEMACARE (www.rarecarenet.eu; www.haemacare.eu). The definition and list of rare cancers proposed by the RARECAREnet "Information Network on Rare Cancers" project were adopted: rare cancers are entities (defined as a combination of topographical and morphological codes of the ICD-O-3) having an incidence rate of less than 6 per 100,000 per year in the European population. This monograph presents 198 rare cancers grouped in 14 major groups. Crude incidence rates were estimated as the number of all new cancers occurring in 2000-2010 divided by the overall population at risk, for males and females (also for gender-specific tumours).The proportion of rare cancers out of the total cancers (rare and common) by site was also calculated. Incidence rates by sex and age are reported. The expected number of new cases in 2015 in Italy was estimated assuming the incidence in Italy to be the same as in the AIRTUM area. One- and 5-year relative survival estimates of cases aged 0-99 years diagnosed between 2000 and 2008 in the AIRTUM database, and followed up to 31 December 2009, were calculated using complete cohort survival analysis. To estimate the observed prevalence in Italy, incidence and follow-up data from 11 CRs for the period 1992-2006 were used, with a prevalence index date of 1 January 2007. Observed prevalence in the general population was disentangled by time prior to the reference date (≤2 years, 2-5 years, ≤15 years). To calculate the complete prevalence proportion at 1 January 2007 in Italy, the 15-year observed prevalence was corrected by the completeness index, in order to account for those cancer survivors diagnosed before the cancer registry activity started. The completeness index by cancer and age was obtained by means of statistical regression models, using incidence and survival data available in the European RARECAREnet data. RESULTS: In total, 339,403 tumours were included in the incidence analysis. The annual incidence rate (IR) of all 198 rare cancers in the period 2000-2010 was 147 per 100,000 per year, corresponding to about 89,000 new diagnoses in Italy each year, accounting for 25% of all cancer. Five cancers, rare at European level, were not rare in Italy because their IR was higher than 6 per 100,000; these tumours were: diffuse large B-cell lymphoma and squamous cell carcinoma of larynx (whose IRs in Italy were 7 per 100,000), multiple myeloma (IR: 8 per 100,000), hepatocellular carcinoma (IR: 9 per 100,000) and carcinoma of thyroid gland (IR: 14 per 100,000). Among the remaining 193 rare cancers, more than two thirds (No. 139) had an annual IR <0.5 per 100,000, accounting for about 7,100 new cancers cases; for 25 cancer types, the IR ranged between 0.5 and 1 per 100,000, accounting for about 10,000 new diagnoses; while for 29 cancer types the IR was between 1 and 6 per 100,000, accounting for about 41,000 new cancer cases. Among all rare cancers diagnosed in Italy, 7% were rare haematological diseases (IR: 41 per 100,000), 18% were solid rare cancers. Among the latter, the rare epithelial tumours of the digestive system were the most common (23%, IR: 26 per 100,000), followed by epithelial tumours of head and neck (17%, IR: 19) and rare cancers of the female genital system (17%, IR: 17), endocrine tumours (13% including thyroid carcinomas and less than 1% with an IR of 0.4 excluding thyroid carcinomas), sarcomas (8%, IR: 9 per 100,000), central nervous system tumours and rare epithelial tumours of the thoracic cavity (5%with an IR equal to 6 and 5 per 100,000, respectively). The remaining (rare male genital tumours, IR: 4 per 100,000; tumours of eye, IR: 0.7 per 100,000; neuroendocrine tumours, IR: 4 per 100,000; embryonal tumours, IR: 0.4 per 100,000; rare skin tumours and malignant melanoma of mucosae, IR: 0.8 per 100,000) each constituted <4% of all solid rare cancers. Patients with rare cancers were on average younger than those with common cancers. Essentially, all childhood cancers were rare, while after age 40 years, the common cancers (breast, prostate, colon, rectum, and lung) became increasingly more frequent. For 254,821 rare cancers diagnosed in 2000-2008, 5-year RS was on average 55%, lower than the corresponding figures for patients with common cancers (68%). RS was lower for rare cancers than for common cancers at 1 year and continued to diverge up to 3 years, while the gap remained constant from 3 to 5 years after diagnosis. For rare and common cancers, survival decreased with increasing age. Five-year RS was similar and high for both rare and common cancers up to 54 years; it decreased with age, especially after 54 years, with the elderly (75+ years) having a 37% and 20% lower survival than those aged 55-64 years for rare and common cancers, respectively. We estimated that about 900,000 people were alive in Italy with a previous diagnosis of a rare cancer in 2010 (prevalence). The highest prevalence was observed for rare haematological diseases (278 per 100,000) and rare tumours of the female genital system (265 per 100,000). Very low prevalence (<10 prt 100,000) was observed for rare epithelial skin cancers, for rare epithelial tumours of the digestive system and rare epithelial tumours of the thoracic cavity. COMMENTS: One in four cancers cases diagnosed in Italy is a rare cancer, in agreement with estimates of 24% calculated in Europe overall. In Italy, the group of all rare cancers combined, include 5 cancer types with an IR>6 per 100,000 in Italy, in particular thyroid cancer (IR: 14 per 100,000).The exclusion of thyroid carcinoma from rare cancers reduces the proportion of them in Italy in 2010 to 22%. Differences in incidence across population can be due to the different distribution of risk factors (whether environmental, lifestyle, occupational, or genetic), heterogeneous diagnostic intensity activity, as well as different diagnostic capacity; moreover heterogeneity in accuracy of registration may determine some minor differences in the account of rare cancers. Rare cancers had worse prognosis than common cancers at 1, 3, and 5 years from diagnosis. Differences between rare and common cancers were small 1 year after diagnosis, but survival for rare cancers declined more markedly thereafter, consistent with the idea that treatments for rare cancers are less effective than those for common cancers. However, differences in stage at diagnosis could not be excluded, as 1- and 3-year RS for rare cancers was lower than the corresponding figures for common cancers. Moreover, rare cancers include many cancer entities with a bad prognosis (5-year RS <50%): cancer of head and neck, oesophagus, small intestine, ovary, brain, biliary tract, liver, pleura, multiple myeloma, acute myeloid and lymphatic leukaemia; in contrast, most common cancer cases are breast, prostate, and colorectal cancers, which have a good prognosis. The high prevalence observed for rare haematological diseases and rare tumours of the female genital system is due to their high incidence (the majority of haematological diseases are rare and gynaecological cancers added up to fairly high incidence rates) and relatively good prognosis. The low prevalence of rare epithelial tumours of the digestive system was due to the low survival rates of the majority of tumours included in this group (oesophagus, stomach, small intestine, pancreas, and liver), regardless of the high incidence rate of rare epithelial cancers of these sites. This AIRTUM study confirms that rare cancers are a major public health problem in Italy and provides quantitative estimations, for the first time in Italy, to a problem long known to exist. This monograph provides detailed epidemiologic indicators for almost 200 rare cancers, the majority of which (72%) are very rare (IR<0.5 per 100,000). These data are of major interest for different stakeholders. Health care planners can find useful information herein to properly plan and think of how to reorganise health care services. Researchers now have numbers to design clinical trials considering alternative study designs and statistical approaches. Population-based cancer registries with good quality data are the best source of information to describe the rare cancer burden in a population.
Assuntos
Neoplasias/epidemiologia , Neoplasias/prevenção & controle , Adolescente , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Neoplasias do Sistema Nervoso Central/epidemiologia , Neoplasias do Sistema Nervoso Central/prevenção & controle , Criança , Pré-Escolar , Bases de Dados Factuais , Neoplasias do Sistema Digestório/epidemiologia , Neoplasias do Sistema Digestório/prevenção & controle , Neoplasias das Glândulas Endócrinas/epidemiologia , Neoplasias das Glândulas Endócrinas/prevenção & controle , Europa (Continente)/epidemiologia , Neoplasias Oculares/epidemiologia , Neoplasias Oculares/prevenção & controle , Feminino , Seguimentos , Neoplasias dos Genitais Masculinos/epidemiologia , Neoplasias dos Genitais Masculinos/prevenção & controle , Neoplasias de Cabeça e Pescoço/epidemiologia , Neoplasias de Cabeça e Pescoço/prevenção & controle , Humanos , Incidência , Lactente , Recém-Nascido , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Neoplasias/diagnóstico , Neoplasias/mortalidade , Neoplasias Embrionárias de Células Germinativas/epidemiologia , Neoplasias Embrionárias de Células Germinativas/prevenção & controle , Neoplasias Epiteliais e Glandulares/epidemiologia , Neoplasias Epiteliais e Glandulares/prevenção & controle , Tumores Neuroendócrinos/epidemiologia , Tumores Neuroendócrinos/prevenção & controle , Prevalência , Sistema de Registros/estatística & dados numéricos , Estudos Retrospectivos , Fatores de Risco , Distribuição por Sexo , Taxa de Sobrevida , Neoplasias Torácicas/epidemiologia , Neoplasias Torácicas/prevenção & controleRESUMO
Xeroderma pigmentosum (XP) is a rare autosomal recessive disease of deoxyribonucleic acid (DNA) repair with ultraviolet (UV) radiation sensitivity and a 10 000-fold increased risk of skin cancer. Symptoms include: freckle-like pigmentation in sun-exposed skin before age 2 years, severe burns after minimal sun exposure (50% of patients) and damage to exposed surfaces of the eyes with loss of vision and ocular cancer. About 25% of patients develop a progressive neurodegeneration. The combination of an inherited inability to repair UV-induced DNA damage and environmental exposure to UV must occur for cutaneous and ocular symptoms to develop. There is no cure for XP, but many of its manifestations may be reduced or prevented through consistent UV protection; thus XP serves as a model for sun protection of patients with marked photosenstivity. Sun protective clothing including hats, sunglasses and face shields, sun screen lotions and avoidance of environmental sources of UV are cornerstones of prevention of skin and eye damage and cancer. Although XP is a serious disease with the potential for limitation of life expectancy, XP patients can live active lives while at the same time avoiding UV.
Assuntos
Cegueira/prevenção & controle , Dano ao DNA , Neoplasias Oculares/prevenção & controle , Neoplasias Cutâneas/prevenção & controle , Pigmentação da Pele , Protetores Solares/uso terapêutico , Xeroderma Pigmentoso , Animais , Humanos , Pigmentação da Pele/efeitos dos fármacos , Pigmentação da Pele/efeitos da radiaçãoRESUMO
The goal of radiotherapy is to produce maximal damage to the tumor yet at the same time produce minimal damage to the surrounding tissues. Here we discuss anterior chamber complications of radiotherapy. These can vary from ocular surface irritation to blindness and can be subdivided into acute (<4 weeks) and chronic (>4 weeks). Prevention and management is also discussed and subdivided by affected tissue.
Assuntos
Segmento Anterior do Olho/efeitos da radiação , Neoplasias Oculares/radioterapia , Lesões por Radiação/etiologia , Radioterapia/efeitos adversos , Neoplasias Oculares/prevenção & controle , Humanos , Lesões por Radiação/prevenção & controleAssuntos
Crise Blástica/patologia , Neoplasias Oculares/patologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Crise Blástica/líquido cefalorraquidiano , Crise Blástica/prevenção & controle , Ciclofosfamida/administração & dosagem , Citarabina/administração & dosagem , Doxorrubicina/administração & dosagem , Neoplasias Oculares/líquido cefalorraquidiano , Neoplasias Oculares/prevenção & controle , Evolução Fatal , Feminino , Humanos , Mercaptopurina/administração & dosagem , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Leucemia-Linfoma Linfoblástico de Células Precursoras/líquido cefalorraquidiano , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevenção & controle , Recidiva , Vincristina/administração & dosagemRESUMO
Sun protection is a major concern for outdoor workers as they are particularly exposed to solar ultraviolet radiation and therefore at increased risk of developing some forms of skin cancer, cataract and ocular neoplasm. In order to provide an overview of outdoor workers' sun-related knowledge, attitudes and protective behaviours as reported in the literature and to evaluate the effectiveness of sun-safety education programmes in outdoor occupational settings, we conducted a systematic review of the literature by searching three electronic databases (PubMed, Embase, PsycINFO) from their inception up to 25 April 2012. An extensive hand search complemented the database searches. We identified 34 relevant articles on descriptive studies and 18 articles on interventional studies. Considerable numbers of outdoor workers were found to have sun-sensitive skin types; sunburn rates per season ranged from 50% to 80%. Data concerning outdoor workers' sun-related knowledge and attitudes were scarce and controversial. The reported sun-protective behaviours were largely inadequate, with many workers stating that they never or only rarely wore a long-sleeved shirt (50-80%), sun-protective headgear (30-80%) and sunscreen (30-100%) while working in the sun. However, there is growing evidence that occupational sun-safety education is effective in increasing outdoor workers' sun-protection habits and presumably in decreasing sunburn rates. Occupational sun-safety education programmes offer great potential for improving outdoor workers' largely insufficient sun-protective behaviours. It is hoped that, in the future, committed support from healthcare authorities, cancer foundations, employers and dermatologists will open the way for rapid and uncomplicated implementation of sun-safety education programmes.
Assuntos
Catarata/prevenção & controle , Conhecimentos, Atitudes e Prática em Saúde , Roupa de Proteção/estatística & dados numéricos , Luz Solar/efeitos adversos , Protetores Solares/uso terapêutico , Raios Ultravioleta/efeitos adversos , Neoplasias Oculares/prevenção & controle , Comportamentos Relacionados com a Saúde , Humanos , Exposição Ocupacional/efeitos adversos , Risco , Neoplasias Cutâneas/prevenção & controle , Queimadura Solar/prevenção & controleRESUMO
To characterize mechanisms of CTL inhibition within an ocular tumor microenvironment, tumor-specific CTLs were transferred into mice with tumors developing within the anterior chamber of the eye or skin. Ocular tumors were resistant to CTL transfer therapy whereas skin tumors were sensitive. CTLs infiltrated ocular tumors at higher CTL/tumor ratios than in skin tumors and demonstrated comparable ex vivo effector function to CTLs within skin tumors indicating that ocular tumor progression was not due to decreased CTL accumulation or inhibited CTL function within the eye. CD11b(+)Gr-1(+)F4/80(-) cells predominated within ocular tumors, whereas skin tumors were primarily infiltrated by CD11b(+)Gr-1(-)F4/80(+) macrophages (Ms), suggesting that myeloid derived suppressor cells may contribute to ocular tumor growth. However, CD11b(+) myeloid cells isolated from either tumor site suppressed CTL activity in vitro via NO production. Paradoxically, the regression of skin tumors by CTL transfer therapy required NO production by intratumoral Ms indicating that NO-producing intratumoral myeloid cells did not suppress the effector phase of CTL. Upon CTL transfer, tumoricidal concentrations of NO were only produced by skin tumor-associated Ms though ocular tumor-associated Ms demonstrated comparable expression of inducible NO synthase protein suggesting that NO synthase enzymatic activity was compromised within the eye. Correspondingly, in vitro-activated Ms limited tumor growth when co-injected with tumor cells in the skin but not in the eye. In conclusion, the decreased capacity of Ms to produce NO within the ocular microenvironment limits CTL tumoricidal activity allowing ocular tumors to progress.
Assuntos
Neoplasias Oculares/prevenção & controle , Leucemia Experimental/prevenção & controle , Linfoma de Células T/prevenção & controle , Macrófagos/imunologia , Óxido Nítrico/biossíntese , Óxido Nítrico/toxicidade , Neoplasias Cutâneas/prevenção & controle , Linfócitos T Citotóxicos/imunologia , Animais , Linhagem Celular Tumoral , Citocinas/biossíntese , Grânulos Citoplasmáticos/imunologia , Grânulos Citoplasmáticos/metabolismo , Exocitose/imunologia , Neoplasias Oculares/imunologia , Neoplasias Oculares/patologia , Feminino , Leucemia Experimental/imunologia , Leucemia Experimental/patologia , Linfoma de Células T/imunologia , Linfoma de Células T/patologia , Ativação de Macrófagos/imunologia , Macrófagos/metabolismo , Macrófagos/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Transgênicos , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/patologia , Linfócitos T Citotóxicos/transplanteRESUMO
Little is known on the ability of different epithelia to release soluble TNF-related apoptosis-inducing ligand (TRAIL) and the relevance of TRAIL secretion by epithelial cells is still incompletely understood. On these bases, we have measured the concentration of soluble TRAIL by ELISA in the conjunctival sac fluid. It was the highest ever detected in a biological fluid (mean value of 26,800 pg/ml), being approximately 20-fold greater than that found in human saliva and >200-fold greater than that detected in human serum. On the other hand, osteoprotegerin, the soluble decoy receptor of TRAIL, was almost undetectable in the conjunctival sac fluid. Of note, the levels of soluble TRAIL measured in conjunctival sac fluid were in the range able to induce in vitro apoptosis of lymphoma cells. By in situ immunohistochemistry, TRAIL protein expression was predominantly detected in the corneal epithelium and, to a less extent, in the conjunctival epithelium. By flow cytometry analysis, membrane-associated TRAIL was documented in isolated corneal epithelial cells obtained from patients undergoing photorefractive keratectomy (PRK). The key contribution provided by corneal epithelium to the production of soluble TRAIL was underscored in time-course experiments, in which a marked decrease of the levels of soluble TRAIL in the conjunctival sac fluid was demonstrated 1 day after PRK followed by a progressive recovery at days 5-30 after PRK. Taken together, our findings strongly support a major role of soluble TRAIL in protecting cornea and conjunctiva from tumor formation and/or invasion.
Assuntos
Túnica Conjuntiva/metabolismo , Ligante Indutor de Apoptose Relacionado a TNF/metabolismo , Apoptose/efeitos dos fármacos , Apoptose/fisiologia , Líquidos Corporais/metabolismo , Linhagem Celular Tumoral , Córnea/citologia , Córnea/metabolismo , Células Epiteliais/citologia , Células Epiteliais/metabolismo , Neoplasias Oculares/prevenção & controle , Humanos , Técnicas In Vitro , Osteoprotegerina/metabolismo , Ceratectomia Fotorrefrativa , Proteínas Recombinantes/farmacologia , Solubilidade , Ligante Indutor de Apoptose Relacionado a TNF/farmacologiaRESUMO
The role of human papillomavirus (HPV) infection in eye disease is controversial. However, a recent case illustrates the possible role of HPV in conjunctival squamous carcinoma and the potentially devastating effects of this disease. The development of two vaccines to prevent infection with HPV types most commonly associated with anogenital cancers has led to debate about the pros and cons of a national immunisation programme to prevent cervical cancer. The introduction of such a vaccination programme may have an additional beneficial effect on the occurrence of some head and neck, including ocular, cancers. This review discusses the nature of papillomaviruses, mechanisms of infection and carcinogenesis, the possible role of HPV in eye disease, and finally the likely impact of the new prophylactic vaccines.
Assuntos
Infecções Oculares Virais/prevenção & controle , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus , Transformação Celular Neoplásica , Transformação Celular Viral , Neoplasias Oculares/prevenção & controle , Neoplasias Oculares/virologia , Humanos , Papillomaviridae/classificação , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/complicaçõesRESUMO
Although intraocular tumours reside in an immune-privileged site, they can circumvent immune privilege and undergo rejection. Ocular tumour rejection typically follows one of two pathways. One pathway involves CD4+ T cells, delayed-type hypersensitivity (DTH), and culmination in ischemic necrosis of the tumour and phthisis (atrophy) of the eye. The second pathway is DTH-independent and does not inflict collateral injury to ocular tissues, and the eye is preserved. In this study, we used a well-characterized tumour, Ad5E1, to investigate the role of CD4+ T cells in the non-phthisical form of intraocular tumour rejection. It has been previously documented that CD4+ T cells and interferon (IFN)-gamma are necessary for rejection of these tumours in the eye. In this study, we demonstrate that CD4+ T cells can circumvent immune privilege and infiltrate intraocular Ad5E1 tumours. Following tumour rejection, CD4+ T cells from tumour rejector mice could be adoptively transferred to severe combined immunodeficiency (SCID) mice and protect them from intraocular Ad5E1 tumour growth. Tumour-specific CD4+ T cells produced IFN-gamma in response to Ad5E1 tumour antigens. Macrophages also contributed to rejection, as they were present in intraocular Ad5E1 tumours, and local depletion of macrophages resulted in progressive tumour growth. Ocular macrophages contributed to Ad5E1 tumour rejection, as Ad5E1 tumour rejection did not occur in macrophage-depleted SCID mice reconstituted with rejector CD4+ T cells. This demonstrates that macrophage and CD4+ T-cell co-operation is needed for non-phthisical rejection of intraocular tumours.
Assuntos
Linfócitos T CD4-Positivos/imunologia , Neoplasias Oculares/imunologia , Macrófagos/imunologia , Transferência Adotiva , Animais , Células Cultivadas , Citotoxicidade Imunológica/imunologia , Progressão da Doença , Ensaio de Imunoadsorção Enzimática/métodos , Neoplasias Oculares/patologia , Neoplasias Oculares/prevenção & controle , Hipersensibilidade Tardia/imunologia , Interferon gama/imunologia , Células Matadoras Naturais/imunologia , Ativação Linfocitária/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos SCID , Transplante de NeoplasiasRESUMO
Although intraocular tumors reside in an immune-privileged environment, T cells can circumvent immune privilege and mediate tumor rejection without inducing damage to normal ocular tissue. In this study, we used a well-characterized tumor, Ad5E1 (adenovirus type 5 early region 1), to analyze the role of CD8+ T cells in the pristine rejection of intraocular tumors. It has been previously documented that Ad5E1 tumor rejection can occur in the absence of CD8+ T cells. However, here we find that CD8+ T cells infiltrated intraocular Ad5E1 tumors in C57BL/6 mice. Surprisingly, CD8+ T cells from tumor-rejector mice could mediate intraocular tumor rejection following adoptive transfer to SCID mice. In determining the mechanisms behind CD8+ T cell-mediated tumor rejection, we discovered that antitumor CTL activity was neither observed nor necessary for rejection of the intraocular tumors. CD8+ T cells from rejector mice did not produce IFN-gamma in response to Ad5E1 tumor Ags or use FasL to mediate intraocular tumor rejection. Also, CD8+ T cells did not use perforin or TRAIL, as CD8+ T cells from perforin knockout (KO) and TRAIL KO mice conferred protection to SCID recipient mice following adoptive transfer. We discovered that CD8+ T cells used TNF-alpha to mediate tumor rejection, because Ad5E1 tumor cells were highly sensitive to TNF-alpha-induced apoptosis and CD8+ T cells from TNF-alpha KO mice did not protect SCID mice from progressive Ad5E1 tumor growth. The results indicate that CD8+ T cells circumvent immune privilege and mediate intraocular tumor rejection by a TNF-alpha-dependent manner while leaving the eye intact and vision preserved.
Assuntos
Câmara Anterior/imunologia , Câmara Anterior/virologia , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/metabolismo , Neoplasias Oculares/imunologia , Neoplasias Oculares/prevenção & controle , Rejeição de Enxerto/imunologia , Fator de Necrose Tumoral alfa/fisiologia , Adenovírus Humanos/imunologia , Animais , Câmara Anterior/patologia , Linfócitos T CD8-Positivos/patologia , Linhagem Celular Tumoral , Movimento Celular/imunologia , Neoplasias Oculares/patologia , Neoplasias Oculares/virologia , Rejeição de Enxerto/genética , Rejeição de Enxerto/patologia , Rejeição de Enxerto/virologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Camundongos Knockout , Camundongos SCID , Transplante de Neoplasias/imunologia , Sarcoma Experimental/imunologia , Sarcoma Experimental/patologia , Sarcoma Experimental/prevenção & controle , Fator de Necrose Tumoral alfa/deficiência , Fator de Necrose Tumoral alfa/genéticaRESUMO
Dr. Robert C. Allen was a gifted educator, as well as experienced ophthalmologist, who was a close personal friend of Dr. Edlich at the University of Virginia Health System. While serving on the faculty at the University of Virginia Health System, Dr. Allen proved to be a compassionate physician, who developed close personal relationships with the residents, faculty, and his patients. Dr. Allen was invited by Dr Edlich to be a member of the Editorial Board of the Journal of Long-Term Effects of Medical Implants. When Dr. Allen told Dr. Edlich that he had ocular melanoma in 2000, this news was a wake-up call to Dr. Edlich on the need to prevent skin cancer, as well as ocular melanoma. Empowered by this news, Dr. Edlich was honored to co-author four articles on skin cancer prevention, as well as the latest article focusing on prevention of ocular melanoma. The Ocular Melanoma Foundation (Richmond, VA (USA)) was founded in 2003 by Dr. Robert C. Allen to increase awareness, enhance education, and provide advocacy among both patients and health care professionals regarding this rare, but potentially lethal cancer. It has a website that provides patient information, up-to-date information and enables communication/ discourse between and among patients and practitioners (admin@ocularmelanoma.org). Dr. Allen died on March 24, 2005, at his home surrounded by family and loved ones. When surgeons are faced with challenging healthcare diseases, Dr. Edlich's mentor, Dr. Owen Wangensteen, advised Dr. Edlich that he should seek the advice and guidance of skilled basic scientists, who are familiar with the problem. Dr. Wangensteen is recognized as the greatest surgical teacher during the 20th century. Consequently, Dr. Edlich enlisted the advice and guidance from the two co-authors of the next article regarding the scientific basis for the selection of sunglasses to prevent the development of cataracts, pterygia, skin cancer, as well as ocular melanoma. Dr. Reichow is a Professor of Optometry at Pacific University College of Optometry (Forest Grove, OR (USA)). Dr. Citek is Associate Professor of Optometry at Pacific University College of Optometry (Forest Grove (USA)). In their comprehensive evaluation of sunglasses, they found some disturbing results. Despite being endorsed by The Skin Cancer Foundation, the Walgreens eyewear samples offer only partial protection to the potential hazards of sunlight exposure. Those individuals who spend considerable time outdoors should seek sun filter eyewear with impact resistant polycarbonate lenses that provide 100% ultraviolet filtration, high levels of blue light filtration, and full visual field lens/frame coverage as provided by high wrap eyewear. There are several brands that offer products with such protective characteristics. Performance sun eyewear by Nike Vision (Nike Inc., Portland OR [USA]), available in both corrective and plano (nonprescription) forms, is one such brand incorporating these protective features, as well as patented optical and tint designs. Numerous Nike styles offer interchangeable lens options to meet the changing environmental conditions encountered outdoors. These technologies are incorporated into performance-driven frame designs inspired by feedback from some of the world's best athletes. Nonprescription Nike eyewear are available on-line at http://www.nike.com/nikevision, as well as at various well-known retail outlets. Nonprescription and prescription Nike eyewear are also available at the offices of many eye care professionals. Even though our latest report did not include soft contact lens, it is important to emphasize that Dr. Reichow and Dr. Citek have played a leadership role in coordinating the development of the Nike MAXSIGHT, an innovative fully tinted soft contact lens. This contact lens provides distortion-free optics, whether or not you wear prescription contacts. They filter out more than 90% of harmful blue light and 95% of UVA and UVB. For the contact lens, you should go to the website for more information http://www.nike.com/nikevision/content.html. The website has a list of practitioners who can service the patients with the respective sunglasses. With their exciting technologic advances in sunglass products, as well as tinted soft contact lens, the authors would encourage Nike Vision to develop an expanded international marketing program that allows all individuals in the world to easily purchase its products.
Assuntos
Oftalmologia/história , Neoplasias Oculares/história , Neoplasias Oculares/prevenção & controle , História do Século XX , História do Século XXI , Humanos , Melanoma/história , Melanoma/prevenção & controle , Estados UnidosRESUMO
Rb family proteins (pRb/p105, Rb2/p130 and p107) play a key role in cell cycle control and are worthily involved in transcription repression and tumor suppression. The mechanisms of transcriptional activation and repression by the Rb gene family has been extensively investigated: pRb, pRb2/p130 and p107 interact with different E2F family factors and can inhibit E2F responsive promoters, interfering with progression of cell cycle, gene transcription, initiation of apoptotic process and cell differentiation. Recent studies have indicated that Rb and Rb2/p130 may be involved in cellular response to DNA damage events, by influencing the transcription of factors involved in DNA repair pathways. In particular, evidences suggest that Rb loss and target gene deregulation impacts on the repair of UV-induced pyrimidine pyrimidone photoproducts (6-4 PP) by regulating the expression of several DNA damage factors involved in UV DNA damage repair processes, including proliferating cell nuclear antigen. Ongoing studies are focused on the mechanisms by which Rb family genes drive cell cycle exit following DNA damage induction, and how Rb gene family's interaction with chromatin remodeling factors can influence DNA repair dynamics.
Assuntos
Ciclo Celular/genética , Neoplasias Oculares , Genes do Retinoblastoma , Retinoblastoma , Animais , Dano ao DNA/efeitos da radiação , Reparo do DNA/efeitos da radiação , Neoplasias Oculares/genética , Neoplasias Oculares/prevenção & controle , Humanos , Família Multigênica , Retinoblastoma/genética , Retinoblastoma/prevenção & controle , Transcrição Gênica , Raios UltravioletaRESUMO
Early studies of the retinoblastoma gene (RB) have uncovered its critical role as a regulator of the G(1)/S cell cycle phase progression. Surprisingly, genetic approaches in mammals and nematodes have also shown RB controls cell lineage specification and aspects of differentiation. The RB gene product accomplishes this by diverse mechanisms such as by interacting with tissue-specific transcription factors, enhancing RNA interference, and modifying chromatin structure. We review recent studies uncovering novel mechanisms by which RB works in several cell lineages and we provide perspectives on how these new findings might relate to RB tumor suppression.
Assuntos
Genes do Retinoblastoma , Animais , Ciclo Celular , Neoplasias Oculares/prevenção & controle , Regulação da Expressão Gênica no Desenvolvimento , Humanos , Pulmão/crescimento & desenvolvimento , Mamíferos/embriologia , Camundongos , Camundongos Knockout , Interferência de RNA , Retinoblastoma/prevenção & controleRESUMO
PURPOSE: Injection of tumor cells transformed by the early region 1 of human adenovirus type 5 (Ad5E1) in the anterior chamber (AC) of C57BL/6 mice leads to intraocular tumor formation. This tumor disappears spontaneously 3 to 4 weeks after tumor inoculation without damaging the neighboring ocular tissues. Previous studies have shown that CD4+ T cells, IFNgamma, and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) play a role in the spontaneous eradication of this particular intraocular tumor. This study was conducted to determine whether macrophages are involved in the natural elimination of this intraocular tumor. METHODS: Ad5E1-expressing tumor cells were inoculated into the AC of syngeneic C57BL/6 mice. Macrophage depletion was obtained by subconjunctival (scj), subcutaneous (sc), or intravenous (iv) injection of clodronate liposomes 2, 8, and 14 days after tumor inoculation. Control C57BL/6 mice received PBS liposomes at similar time points after tumor injection or were left untreated. The presence of macrophages in the AC tumor was determined with the macrophage marker F4/80. RESULTS: Progressive tumor growth was observed in mice that were subconjunctivally depleted of macrophages, whereas spontaneous tumor eradication occurred in all other groups. F4/80 staining was negative in the AC tumors of mice treated scj with clodronate liposomes in contrast to the positive F4/80 staining in the tumors of the other groups. Ad5E1 tumor antigen still reached the tumor-draining lymph nodes (DLNs) of mice locally depleted for macrophages. CONCLUSIONS: Local macrophages in the eye are involved in the process of spontaneous AC tumor eradication in mice. However, it is not conclusive from these data exactly how tumor-specific CD4+ T cells and macrophages interact with each other to eliminate the Ad5E1-AC tumor without any collateral eye damage.
Assuntos
Câmara Anterior/patologia , Neoplasias Oculares/prevenção & controle , Macrófagos/fisiologia , Adenovírus Humanos/fisiologia , Transferência Adotiva , Animais , Antígenos de Diferenciação/metabolismo , Linfócitos T CD4-Positivos/imunologia , Linhagem Celular Tumoral , Transformação Celular Viral , Ácido Clodrônico/administração & dosagem , Neoplasias Oculares/imunologia , Neoplasias Oculares/patologia , Citometria de Fluxo , Fluoresceínas , Vetores Genéticos , Lipossomos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Transplante de Neoplasias , SuccinimidasRESUMO
Ocular immune privilege preserves the visual axis by preventing the induction of sight-threatening nonspecific inflammation. Although privilege is essential for maintaining visual integrity, intraocular tumors exploit the privileged environment and grow progressively within the anterior chamber of the eye. Recently, a large number of laboratories have constructed genetically engineered tumor cell vaccines that express high levels of costimulatory signals. These vaccines are designed to bypass the normal pathways of T-cell activation and directly activate CD8+ tumor-specific T cells. In the following series of experiments, we determined whether a tumor cell vaccine that uses costimulatory signals (CD80 and IL-12) is capable of eliminating tumors within the immune-privileged anterior chamber. As expected, vaccine-immunized mice rejected subcutaneous flank tumors (a non-privileged site). However, the vaccine failed to protect mice from even a small number of tumor cells transplanted into the immune-privileged anterior chamber. Surprisingly, immunized mice that were simultaneously challenged with subcutaneous and anterior chamber tumors were unable to eliminate tumors at either site. The failure of systemic protective immunity coincided with the loss of tumor-specific delayed hypersensitivity and cytotoxic T cells. We conclude that tumor cell vaccines that induce complete protection against tumors in non-immune-privileged sites fail to protect against the same tumor within an ocular immune-privileged site. Moreover, a tumor that escapes elimination within the eye can terminate systemic protective immunity that is induced by the tumor cell vaccine.
Assuntos
Câmara Anterior/imunologia , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Vacinas Anticâncer/administração & dosagem , Neoplasias Oculares/imunologia , Linfócitos do Interstício Tumoral/imunologia , Mastocitoma/imunologia , Animais , Antígenos de Neoplasias/imunologia , Antígeno B7-1/imunologia , Vacinas Anticâncer/imunologia , Linhagem Celular Tumoral , Neoplasias Oculares/prevenção & controle , Feminino , Hipersensibilidade Tardia/imunologia , Imunidade Celular , Imunização , Interleucina-12/imunologia , Teste de Cultura Mista de Linfócitos , Mastocitoma/prevenção & controle , Camundongos , Camundongos Endogâmicos DBA , Camundongos SCID , Transplante de Neoplasias , Linfócitos T Citotóxicos/imunologiaRESUMO
Eight patients with ocular adnexal mucosal-associated lymphpid tissue (MALT) lymphoma were treated with rituximab, at diagnosis (n=5) or relapse (n=3). All untreated patients achieved lymphoma regression, while relapsing patients had no benefit. Four responding patients experienced early relapse. The median time to progression was 5 months. The efficacy of rituximab in ocular adnexal lymphoma is lower than that reported for gastric MALT lymphomas.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Neoplasias Oculares/terapia , Linfoma de Zona Marginal Tipo Células B/tratamento farmacológico , Adulto , Idoso , Anticorpos Monoclonais Murinos , Neoplasias Oculares/patologia , Neoplasias Oculares/prevenção & controle , Feminino , Humanos , Linfoma de Zona Marginal Tipo Células B/patologia , Linfoma de Zona Marginal Tipo Células B/prevenção & controle , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/prevenção & controle , RituximabRESUMO
Incidence rate, age-adjusted and standardized incidence and mortality of malignant eye tumours (METs) in Uzbekistan in 1978-1998 and professional, ethnic, environmental, and geographical factors which could influence it are analyzed. Before 1978, there was no information about patients with METs in Uzbekistan. We gathered 4872 primary new cases, of whom 79.7% (3882 patients) were treated in our department. All samples were statistically tested. Age-adjusted MET incidence has a peak in the 60-69 age subgroup. The highest incidence was in "non-local" ethnic group. Eyelid tumours occurred most frequently, followed by conjunctival, intraocular and orbital tumours. Urban and rural females had higher incidence than urban and rural males. For 10 years, standardized incidence has increased 2.3 and mortality 6.0 times. The highest incidence and mortality were in Karakalpakstan and Khorezm Wiloyat.
Assuntos
Neoplasias Oculares/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Etnicidade/estatística & dados numéricos , Neoplasias Oculares/classificação , Neoplasias Oculares/mortalidade , Neoplasias Oculares/prevenção & controle , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Ocupações/estatística & dados numéricos , Fatores de Risco , Distribuição por Sexo , Taxa de Sobrevida , Uzbequistão/epidemiologiaRESUMO
Although the anterior chamber of the eye expresses immune privilege, some ocular tumors succumb to immune rejection. Previous studies demonstrated that adenovirus-induced tumors, adenovirus type 5 early region 1 (Ad5E1), underwent immune rejection following transplantation into the anterior chamber of syngeneic mice. Intraocular tumor rejection required CD4(+) T cells, but did not require the following: 1) CD8(+) T cells, 2) B cells, 3) TNF, 4) perforin, 5) Fas ligand, or 6) NK cells. This study demonstrates that CD4(+) T cell-dependent tumor rejection does not occur in IFN-gamma-deficient mice. Ad5E1 tumor cells expressed DR5 receptor for TRAIL and were susceptible to TRAIL-induced apoptosis. Although IFN-gamma did not directly induce apoptosis of the tumor cells, it rendered them 3-fold more susceptible to TRAIL-induced apoptosis. Both CD4(+) T cells and corneal endothelial cells expressed TRAIL and induced apoptosis of Ad5E1 tumor cells. The results suggest that Ad5E1 tumor rejection occurs via TRAIL-induced apoptosis as follows: 1) tumor cells express TRAIL-R2 and are susceptible to TRAIL-induced apoptosis, 2) IFN-gamma enhances TRAIL expression on CD4(+) T cells and ocular cells, 3) IFN-gamma enhances tumor cell susceptibility to TRAIL-induced apoptosis, 4) apoptotic tumor cells are found in the eyes of rejector mice, but not in the eyes of IFN-gamma knockout mice that fail to reject intraocular tumors, 5) CD4(+) T cells and corneal endothelial cells express TRAIL and induce apoptosis of tumor cells, and 6) apoptosis induced by either CD4(+) T cells or corneal cells can be blocked with anti-TRAIL Ab.
Assuntos
Câmara Anterior/imunologia , Câmara Anterior/patologia , Linfócitos T CD4-Positivos/imunologia , Neoplasias Oculares/imunologia , Neoplasias Oculares/prevenção & controle , Interferon gama/fisiologia , Glicoproteínas de Membrana/fisiologia , Fator de Necrose Tumoral alfa/fisiologia , Adenovírus Humanos/genética , Adenovírus Humanos/imunologia , Animais , Câmara Anterior/metabolismo , Apoptose/genética , Apoptose/imunologia , Proteínas Reguladoras de Apoptose , Divisão Celular/genética , Divisão Celular/imunologia , Linhagem Celular Transformada , Linhagem Celular Tumoral , Transformação Celular Viral/genética , Transformação Celular Viral/imunologia , Neoplasias Oculares/genética , Neoplasias Oculares/patologia , Vetores Genéticos , Interferon gama/deficiência , Interferon gama/genética , Glicoproteínas de Membrana/biossíntese , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Transplante de Neoplasias , Técnicas de Cultura de Órgãos , Ligante Indutor de Apoptose Relacionado a TNF , Fator de Necrose Tumoral alfa/biossínteseRESUMO
OBJECTIVES: To identify risk factors for metastatic disease on histopathologic specimens of enucleated eyes from patients with unilateral retinoblastoma, and to evaluate the value of chemoprophylaxis in preventing disease dissemination. METHODS: Medical records from patients with unilateral retinoblastoma who underwent primary enucleation were reviewed at the University of California, San Francisco (1977-1998) and Bascom Palmer Eye Institute, University of Miami, Miami, Fla (1991-1998). All routine histopathologic specimens were reexamined. The extent of tumor invasion into the optic nerve or ocular coats and the prescribed chemoprophylactic regimen were recorded. RESULTS: This retrospective study included 129 patients followed for a median of 54 months. Three patients had tumor invading the sclera. The optic nerve was involved to some extent in 82 patients, 11 of whom had tumor extension beyond the lamina cribrosa. The surgical margin of the optic nerve was involved in an additional 4 patients. The choroid was involved in 43 patients, and was considered massively affected in 12 patients. Anterior segment involvement was observed in 10 patients. Postenucleation chemoprophylaxis was administered to 4 of 4 patients who had tumor cells at the surgical margin of the optic nerve and to 7 of 11 patients with postlaminar disease, all of whom had at least 1 mm of postlaminar tumor extension. External beam radiotherapy was administered to 3/4 and 1/11 of these patients, respectively. Chemoprophylaxis was not administered to patients with choroidal or anterior chamber involvement unless the optic nerve was also involved beyond the lamina cribrosa. One patient with tumor extending to the surgical margin of the optic nerve died of metastatic disease. CONCLUSIONS: Chemoprophylaxis is necessary for patients with tumor extending to the surgical margin of the optic nerve and is likely to be beneficial in preventing metastases in patients with tumor extending beyond the lamina cribrosa. We did not offer chemoprophylaxis to patients with prelaminar optic nerve disease or isolated choroidal involvement, and these patients remained free of disseminated disease.